I. Call to Order.................................................................Marty McKay

II. Parliamentary Business .............................................Marty McKay
   A. Introduction of Members/Roll Call and DHH Staff
   B. Approval of May 2, 2012 Meeting Minutes
   C. Bylaws Subcommittee Report/Update

III. P & T Committee Overview ......................................Kim Sullivan
   A. P & T Background
   B. P & T Bylaws
   C. Ethics Review

IV. Reports.................................................................Rachel Broussard
   A. Prior Authorization Monthly Report
   B. PDL Reflecting May 2, 2012 P&T Committee Recommendations
   C. Travel Regulations 2012-2013

V. New Business.........................................................Calder Lynch/Chris Andrews
   A. LA Pharmacy Reimbursement Change
   B. Pharmacy’s Incorporation Into Managed Care
   C. Therapeutic Class Reviews/Drug Manufacturer Testimony
      1. Alzheimers Agents
      2. Antidepressants, Other
      3. Antidepressants, SSRIs
      4. Antihistamines, Minimally Sedating
      5. Antihypertensives, Sympatholytic (New)
      6. Antihyperuricemics, Oral
      7. Antiparkinsons Agents
      8. Antipsychotics
      9. Antipsoriatrics, Topical (New)
     10. Bile Salts
     11. Bronchodilators, Beta Agonist
     12. COPD Agents
     13. Cytokine And CAM Antagonists
     14. Emollients (New)
     15. Glucocorticoids, Inhaled
     16. Immunomodulators, Atopic Dermatitis
     17. Intranasal Rhinitis Agents
     18. Leukotriene Modifiers
     19. Neuropathic Pain
     20. NSAIDs
     21. Oncology Agents, Oral
     22. Ophthalmic Antibiotic/Steroid Combinations
23. Ophthalmic Antibiotics
24. Ophthalmics For Allergic Conjunctivitis
25. Ophthalmics, Anti-Inflammatories
26. Ophthalmics, Glaucoma Agents
27. Otic Antibiotics
28. Otic Anti-Infectives
29. Sedative Hypnotics
30. Smoking Cessation
31. Steroids, Topical - High
32. Steroids, Topical - Low
33. Steroids, Topical - Medium
34. Steroids, Topical – Very High
35. Stimulants and Related Agents

VI. New Single Drug Reviews in Current PDL Categories………………………..Chris Andrews
   1. Analgesics, Narcotic Short - Primalev
   2. Analgesics, Narcotic Short - Subsys
   3. Hypoglycemics, Incretin Mimetics/Enhancers - Bydureon
   4. Antiparasitics, Topical - Sklice
   5. Bladder Relaxants - Gelnique gel pump
   6. Erythropoiesis Stimulating Proteins - Omontys

VII. Other Business

VIII. Next Steps
   A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – May 1, 2013

X. Public Testimony